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Dengue virus (DENV) infection is considered a major public health problem in developing tropical countries where the virus is
endemic and continues to cause major disease outbreaks every year. Here, we describe the development of a novel, inexpensive,
and user-friendly diagnostic assay based on a reverse transcription-insulated isothermal PCR (RT-iiPCR) method for the detec-
tion of all four serotypes of DENV in clinical samples. The diagnostic performance of the newly established pan-DENV RT-iiPCR
assay targeting a conserved 3= untranslated region of the viral genome was evaluated. The limit of detection with a 95% confi-
dence was estimated to be 10 copies of in vitro-transcribed (IVT) RNA. Sensitivity analysis using RNA prepared from 10-fold
serial dilutions of tissue culture fluid containing DENVs suggested that the RT-iiPCR assay was comparable to the multiplex
real-time quantitative RT-PCR (qRT-PCR) assay for DENV-1, -3, and -4 detection but 10-fold less sensitive for DENV-2 detec-
tion. Subsequently, plasma collected from patients suspected of dengue virus infection (n 220) and individuals not suspected
of dengue virus infection (n 45) were tested by the RT-iiPCR and compared to original test results using a DENVNS1 antigen
rapid test and the qRT-PCR. The diagnostic agreement of the pan-DENV RT-iiPCR, NS1 antigen rapid test, and qRT-PCR tests
was 93.9%, 84.5%, and 97.4%, respectively, compared to the composite reference results. This new RT-iiPCR assay along with the
portable POCKIT nucleic acid analyzer could provide a highly reliable, sensitive, and specific point-of-need diagnostic assay for
the diagnosis of DENV in clinics and hospitals in developing countries.
Dengue virus (DENV) is a mosquito-borne human pathogenthat belongs to the genus Flavivirus in the family Flaviviridae
(1). DENV is an enveloped virus with a single-stranded, positive-
sense RNA genome approximately 10.7 kb in length (2). The
genomic RNA includes 5= and 3=untranslated regions (UTRs) and
a single open reading frame that encodes a single polyprotein that
is cleaved into three structural proteins (capsid [C], premem-
brane/membrane [prM/M], and envelope [E]) and seven non-
structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5) (3). DENV is comprised of four distinct serotypes (DENV-1,
-2, -3, and -4), and all four serotypes are currently circulating in
the Pacific Islands, Americas, Asia, and Africa. In addition to this,
distinct genotypes have been identifiedwithin each serotype (4, 5),
highlighting the extensive genetic variability of the DENV sero-
types.
DENV infection is considered a major public health problem
in developing tropical countries where the virus is endemic, and it
is continuously spreading to new geographical areas around the
world (6, 7). Moreover, frequent international travel to regions
where dengue is endemic or epidemic increases the risk of DENV
infection for travelers (8, 9), and travel contributes to the escalat-
ing numbers of imported dengue cases in temperate regions.More
than 2.5 billion people are at risk ofDENV infection each year, and
an estimated 50 million dengue virus infections occur annually
around the world (10, 11). DENV is primarily transmitted by the
mosquito speciesAedes aegypti, present in tropical and subtropical
regions, and less efficiently by Aedes albopictus (12). The DENV
infection causes a wide range of clinical signs in humans, from
acute febrile illness (dengue fever [DF]) to hemorrhagic fever/
dengue shock syndrome (DHF/DSS), mostly characterized by
plasma leakage with or without hemorrhage (13).
The diagnosis of dengue virus infections cannot rely solely
on clinical manifestations since many patients are either
asymptomatic or present with a nondescript fever requiring dif-
ferential diagnosis to distinguish exposure to DENVs from other
febrile-episode-inducing diseases. Therefore, rapid, accurate, rel-
atively low-cost diagnostic tools for DENV are critical for the con-
firmation of suspected clinical cases, which in turn is the key to
effective disease management and control. Currently, laboratory
confirmation of DENV infection relies on virus isolation in cell
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culture, detection of viral nucleic acid by real-time quantitative
reverse transcriptase PCR (qRT-PCR), NS1 antigen detection,
and/or detection of virus-specific antibodies in paired sera (e.g.,
neutralization test, immunoglobulin M [IgM] capture enzyme
linked immunosorbent assay [MAC-ELISA], and indirect immu-
noglobulin G ELISA) (14–16). Although virus isolation is consid-
ered the gold standard for laboratory diagnosis of dengue virus
infection, it is time-consuming, expensive, and laborious and re-
quires biosafety level 2 (BSL-2)/BSL-3 cell culture facilities with
trained personnel. Thus, ELISA is still the most widely used tech-
nique for serological diagnosis, providing indirect evidence of in-
fection after seroconversion on the secondweek of fever; however,
it cannot distinguish different DENV serotypes. Furthermore, a
number of rapid diagnostic tests targeting NS1 antigen are com-
mercially available; however, false-negative results are still a con-
cern with these assays (17, 18). Molecular diagnostic assays, such
as high-throughput quantitative PCR (qPCR) assays or gel-based
conventional PCR assays, offer a high degree of detection sensitiv-
ity and specificity, but they require laboratories staffedwith skilled
technicians with relatively expensive equipment that are not avail-
able in remote areas or developing countries.
As all potentially exposed individuals require access to rapid
molecular diagnostic assays for the detection of DENV RNA in
clinical specimens such as blood, plasma, or serum, the develop-
ment of DENV-specific point-of-need (PON) diagnostics will
have a major public health impact by improving clinical outcome
and/or by facilitating a significantly more comprehensive dengue
surveillance program. Implementation of a sensitive and specific
PON test for diagnosis of all four serotypes of DENV in primary
care facilities (e.g., clinics and hospitals) is likely to improve pa-
tient care in developing countries. As a result, a rapid, affordable,
and highly sensitive molecular detection system is still needed for
early PON test detection of DENV infection.
Recently, a fluorescent probe hydrolysis-based insulated iso-
thermal PCR (iiPCR) for amplification and detection of nucleic
acid has been described (21). The iiPCR is highly sensitive and
specific for the detection of both DNA and RNA and could be
performedwith a single heating source; thus, it does not require an
expensive thermocycler (20, 21). The PCR mix in a capillary tube
(R-tube; GeneReach USA, Lexington, MA, USA) is heated at the
bottom. Rayleigh-Bénard convection drives fluid cycling through
temperature gradients, and the three PCR steps, namely, denatur-
ation, annealing, and extension, can be completed at different
zones within the capillary tube. Subsequent integration of hydro-
lysis probe technology and an optical detection module into the
device allows automatic detection and interpretation of iiPCR re-
sults (21). Taking advantage of the fluorescent probe-based iiPCR
methodology and a now commercially available reverse transcrip-
tion-iiPCR (RT-iiPCR) instrument, the POCKIT nucleic acid an-
alyzer (GeneReach USA, Lexington, MA, USA), we developed an
RT-iiPCR assay for the detection of DENVRNAof all serotypes in
clinical specimens. The analytical sensitivity, analytical specificity,
and reproducibility of the newly established pan-DENV-specific
RT-iiPCR assay were assessed to determine effectiveness of the
assay for DENV detection. Subsequently, the assay was further
evaluated for clinical sensitivity and specificity using RNA ex-
tracted from human clinical samples (e.g., plasma) in Sri Lanka
and compared to results with a multiplex qRT-PCR assay previ-
ously described by theCenters forDiseaseControl and Prevention
(CDC qRT-PCR; Atlanta, GA, USA) (22).
MATERIALS AND METHODS
Cells and viruses.Madin-Darby canine kidney (MDCK; ATCC CCL-22)
cells andVero E6 (ATCCCRL-1587) cells were purchased from theAmer-
ican Type Culture Collection (ATCC, Manassas, VA, USA) and main-
tained at 37°C in minimum essential medium (MEM; Invitrogen, Carls-
bad, CA, USA) and Dulbecco’s modified Eagle’s medium (Invitrogen),
respectively, supplemented with 10% fetal bovine serum (FBS; Invitro-
gen). The DENV-1 clinical isolate DenKor-02 was kindly provided by the
Korea National Institute of Health, Osong, Republic of Korea (23, 24).
The laboratory DENV strains, DENV-2/KBPV-VR-29, DENV-3/KBPV-
VR-30, and DENV-4/KBPV-VR-31 (serotypes 2, 3, and 4, respectively),
were obtained from the Korea Bank for Pathogenic Viruses (KBPV; Re-
public of Korea [http://kbpv.knrrc.or.kr]) (25). The prototype DENV-1
(Hawaii A), DENV-2 (New Guinea C), DENV-3 (H87), and DENV-4
(H241) strains were purchased from the National Collection of Patho-
genic Viruses, Culture Collections of Public Health England (Salisbury,
Great Britain). Other human viral pathogens included in this study were
West Nile virus (synthetic viral RNA; ATCC VR-3198SD), Japanese en-
cephalitis virus (a gift fromWu-Chun Tu, National Chung Hsin Univer-
sity, Taiwan), hepatitis C virus (synthetic hepatitis C virus RNA, JFH-1,
genotype 2a; derived from pJFH1 full-length cDNA clone obtained from
T. Wakita, Tokyo Metropolitan Institute for Neuroscience, Tokyo, Ja-
pan), influenza virus type A (H1N1, A/Puerto Rico/8/34 [ATCC VR-
1469]), and influenza virus type B (B/Panama/45/1990 [Korea Center for
Disease Control and Prevention]). All DENVs were propagated in Vero
E6 cells (ATCC CRL-1587), and tissue culture fluid (TCF) supernatants
were harvested at 6 to 7 days postinfection. Influenza viruses (type A and
B) were propagated by infection of MDCK cells at 33°C for 3 days. TCF
was clarified by centrifugation (2,000 g, 4°C, 15min), and 1-ml aliquots
were stored at 80°C until further use. Individual virus stocks were
titrated by plaque assays before use.
Clinical specimens. A total of 220 archived plasma specimens from
clinically suspected dengue patients collected over a period of 3 years
(2011 to 2013) were obtained from the Professorial Medical Unit, Teach-
ing Hospital, University of Peradeniya, Peradeniya, Sri Lanka. The sam-
ples were used for routine diagnosis using the SD Bioline dengue NS1
antigen (Ag) rapid test (Standard Diagnostics, Kyonggi-do, South Korea)
assay at the Department of Veterinary Pathobiology, University of Perad-
eniya. Plasma samples collected from subjects not suspected of DENV
infection (n 45) were also included in the study. All the plasma samples
used in this study were stored at20°C until nucleic acid extraction.
Ethics statement. Samples were collected by the Professorial Medical
Unit, TeachingHospital, University of Peradeniya, Peradeniya, Sri Lanka,
as a part of routine practice from clinically suspected dengue patients on
admission for laboratory diagnosis at the Department of Veterinary
Pathobiology, University of Peradeniya, where diagnostic services were
available free of charge. Informed consent was obtained from patients at
the time of sample collection. Approval of the study was provided by the
Ethical Review Committee of the Faculty of Medicine, University of
Peradeniya, Peradeniya, Sri Lanka (2015/EC/65).
Nucleic acid extraction. For analytical sensitivity analysis, TCF sam-
ples containing each of the four DENV serotypes (1, 2, 3, and 4) were
subjected to 10-fold serial dilutions (100 to 107) in cell culture medium.
Subsequently, viral RNA was extracted from 10-fold serial dilutions of
each of the four DENV serotypes. The archived human plasma samples
were subjected to nucleic acid extraction without further dilution. All
samples (TCF and plasma samples) were extracted by using a taco DNA/
RNA extraction kit (GeneReach USA) on a taco 24 device (GeneReach
USA), according to the manufacturer’s instructions. Briefly, 100 l of
TCF or the plasma samples was added into the first well of the extraction
plate before the automatic extraction steps. After the extraction steps were
completed, nucleic acids were eluted with 200 l of elution buffer. All
nucleic acids were placed at80°C until further use.
IVT RNA preparation. The analytical sensitivity of the pan-DENV
RT-iiPCR assay was determined by using in vitro-transcribed (IVT)
RT-iiPCR Assay for Diagnosis of Dengue Virus Infection
June 2016 Volume 54 Number 6 jcm.asm.org 1529Journal of Clinical Microbiology
 o
n
 N
ovem
ber 14, 2017 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
RNA. Briefly, the sequence of the 3= UTR region of the DENV-2
MD944 isolate (nucleotides [nt] 10162 to 10682;GenBank accession
number FM210230.1) was RT-PCR amplified, cloned into the pGEM-T
vector downstream of the T7 promoter sequence, and subsequently used
as the template in in vitro transcription using a MEGAscript T7 kit (Life
Technologies, USA). ResidualDNAwas removed using anAmbionTurbo
DNA-free kit (Applied Biosystems, Grand Island, NY, USA).
Concentration of RNA was measured by a NanoDrop 1000 spectro-
photometer (NanoDrop Technologies, Houston, TX, USA). Single-use
IVT RNA aliquots were stored at80°C. The analytical sensitivity of the
RT-iiPCR was determined using a dilution series (100 to 108 molecules/
reaction) of the IVT RNA. The concentration of the IVT RNA molecules
per microliter was calculated according to the following formula, as de-
scribed before (26): number of IVT RNA molecules/microliter 
(Avogadro’s number  IVT RNA concentration)/IVT RNA molecular
mass, where Avogadro’s number is 6.022 1023, IVT RNA concentration
is measured in grams/microliter, and IVT RNA molecular mass is mea-
sured in grams.
Establishment of pan-DENV RT-iiPCR assay. The pan-DENV RT-
iiPCR was designed on the basis of the previously described probe hydro-
lysis-based POCKIT method (21). The primers and probe targeted a
highly conserved region in the 3=UTR of the DENV genome (see Table S1
in the supplemental material). This conserved region was identified by
aligning 3,530 DENV sequences available in GenBank. The RT-iiPCR
reaction conditions, such as concentrations of primers and probe, Taq
DNA polymerase, and reverse transcriptase, were tested systematically to
obtain the highest sensitivity and specificity. Following optimization of
the RT-iiPCR assay conditions, the reagents, including primers and
probe, were lyophilized and used in this study. Briefly, R-tubes were la-
beled with the sample identification numbers (one tube per test sample).
After the lyophilized premix was reconstituted in 50l of premix buffer B
(GeneReach USA), 5l of the test nucleic acid extract was added. A 50-l
volume of the premix/sample mixture was transferred into a labeled R-
tube, which was sealed subsequently with a cap, spun briefly in a micro-
centrifuge (cubee; GeneReachUSA), and placed into the POCKIT nucleic
acid analyzer (GeneReach USA). The default program, including an RT
step at 50°C for 10 min and an iiPCR step at 95°C for about 30 min, was
completed in less than 1 h. The signal-to-noise (S/N) ratio, i.e., light signal
collected after iiPCR/fluorescent signal collected before iiPCR (21), was
converted automatically to a plus sign, minus sign, or question mark,
according to the default S/N thresholds by the built-in algorithm. The
results were shownon the display screen at the end of the program (Fig. 1).
A question mark indicated that the results were ambiguous and that the
sample should be tested again.
DENV serotype-specific multiplex real-time RT-PCR assays. The
CDC multiplex DENV-1-4 qRT-PCR assay described by Santiago
et al.(22) (here, the CDC qRT-PCR [http://www.cdc.gov/dengue/clinical
Lab/realTime.html]) was performed using a Superscript III Platinum
One-Step RT-PCR System without 6-carboxy-X-rhodamine (ROX) (Life
Technologies) in aQuantStudio 6KFlex real-time PCR system (Life Tech-
nologies). The CDC qRT-PCR assay was run in the multiplex format as
described previously (22). The primers, probes, target genes, and their
specific locations in the DENV genome are listed in Table S1 in the sup-
plemental material. Signals were collected using the 6-carboxyfluorescein
(FAM), hexachlorofluorescein (HEX), Texas Red, and Cy5 channels for
the detection of fluorescence generated from the DENV-1, -2, -3, and -4
probes, which were labeled at the 5= end with FAM, HEX, Texas Red, and
Cy5 fluorescent dyes, respectively. Briefly, each 25-l reaction mixture
included 5l of nucleic acid sample, 12.5l of 2 Premix, 1M forward
and reverse primers for DENV-1 and DENV-3, 0.5 M forward and re-
verse primers for DENV-2 and DENV-4, 180 nM each TaqMan probe,
and 0.5 l of SuperScript III RT/Platinum Taq mix. The thermocycling
program was set up as follows: an RT step at 50°C for 30 min, followed by
95°C for 2 min and 45 cycles of denaturation at 95°C for 15 s and anneal-
ing at 60°C for 1min. Samples generating a threshold cycle (CT) of37 in
duplicates were considered negative. Each run included negative controls
spiked with water and positive controls with the IVT RNA-containing
target sequences.
Dengue virus NS1 antigen detection. All plasma specimens were
tested for DENV infection by the NS1 Ag rapid test (Standard Diag-
nostics). Tests were performed according to the manufacturer’s in-
structions.
Focus-forming assay. Vero cells were seeded in 24-well plates. Ten-
fold dilutions were prepared in Opti-Pro serum-free medium (SFM) (In-
vitrogen) supplementedwith 2%FBS and 4mML-glutamine in duplicate,
and 150 l of each dilution was added to the cells. The plates were incu-
bated for 1 h at 37°C and rocked every 15 min. Unabsorbed virus was
removed by a phosphate-buffered saline (PBS) wash, and after which 1ml
of Opti-MEM (Invitrogen) supplemented with 0.8% methylcellulose
(MC; Fisher Scientific, Pittsburgh, PA, USA), 4 mM L-glutamine, and 50
g/ml penicillin-streptomycin (Invitrogen) was added to each well, fol-
lowed by incubation at 37°C for 3 days. TheMCoverlaywas aspirated, and
the cells were washed with PBS and fixed with methanol at 4°C overnight.
After fixation, the cells were washed with PBS and incubated at 37°C for 1
h with mouse anti-dengue virus NS1 glycoprotein (catalog no. 41616;
Abcam, Cambridge, MA, USA) and mouse anti-dengue virus complex
(catalog no. MAb8705; EMD Millipore, Billerica, MA, USA) antibodies,
followed by incubation with a horseradish peroxidase (HRP)-conjugated
goat anti-mouse IgG1 antibody (catalog no. 1070-05; Southern Biotech,
Birmingham, AL, USA). The plates were developed with a SuperSignal
West Pico chemiluminescent substrate kit (Thermo Scientific, Waltham,
MA, USA) according to the manufacturer’s instructions. Images were
taken using an ImageQuant LAS 4000 (GE Healthcare, Pittsburgh, PA,
USA).
Statistical analysis. Limit of detectionwith 95% confidence (LoD95%)
was determined by statistical probit analysis (a nonlinear regression
model) using the commercial software SPSS, version 14.0 (SPSS, Inc.,
Chicago, IL, USA). The clinical sensitivity and specificity of the assays
described in the study were calculated based on the analysis of the plasma
samples from 220 suspected dengue patients and 45 donors not suspected
of DENV infection. A composite diagnosis of each sample (2 out of 3 tests
based on the CDC qRT-PCR, the NS1 Ag rapid test, and the pan-DENV
RT-iiPCR giving the same result) was used as a reference (27). The degree
of agreement between two assays was assessed by calculating Cohen’s
kappa () values. Sensitivity was calculated as follows: number of true
positives/(number of true positives  number of false negatives). Speci-
ficity was calculated as follows: number of true negatives/(number of true
negatives number of false positives).
RESULTS
Development and optimization of pan-DENV RT-iiPCR. The
pan-DENV RT-iiPCR method, targeting a highly conserved re-
gion in the 3=UTR of the DENV genomewas designed to generate
FIG 1 Data interpretation. An example of results displayed on the monitor is
shown.
Go et al.
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a 110-bp amplicon to be detected by the fluorescent dye-labeled
probe. The reaction conditions, such as concentrations of primers
and probe, Taq DNA polymerase, and reverse transcriptase, were
tested systematically to obtain the highest sensitivity and specific-
ity (data not shown). Following optimization of the assay condi-
tions, the reagents, including primers and probe, were lyophilized
and used in this study as described inMaterials andMethods. The
sensitivity of the established assay was determined by using 10-
fold serial dilutions of the IVT RNA containing the target DENV
sequence. Analysis of replicates showed 20/20 (100%), 19/20
(95%), 5/20 (25%), and 0/20 (0%) positive signals for reaction
mixtures containing 100, 10, 1, and 0 copies of the IVT RNA,
respectively. The LoD95% of the pan-DENV RT-iiPCR estimated
by probit analysis was 10 genome equivalents/reaction.
Comparison of analytical sensitivity, specificity, and perfor-
mance of pan-DENV RT-iiPCR. (i) Analytical sensitivity. The
performance of the pan-DENVRT-iiPCRwas compared to that of
the CDC qRT-PCR assay (22) that had been approved by the FDA
for detection and typing of DENV in suspected, symptomatic
cases in the United States. The analytical sensitivity of the pan-
DENV RT-iiPCR was evaluated by using 10-fold serial (101 to
109) dilutions of the TCF samples containing a DENV field iso-
late (DENV-1/DenKor-02) or three laboratory strains (DENV-2/
KBPV-VR-29, DENV-3/KBPV-VR-30, and DENV-4/KBPV-VR-
31) of known titers (see Table S2a in the supplemental material).
Viral RNAs extracted from 10-fold serial dilutions were analyzed
by both assays in parallel. The 100% detection endpoints of the
pan-DENV RT-iiPCR and the multiplex CDC qRT-PCR were
found both at 2.7  101 focus-forming units (FFU)/ml for the
DENV-1 virus and 4.7  101 FFU/ml for the DENV-2 virus.
Similarly, endpoints of the pan-DENVRT-iiPCRwere observed at
2.0 102 and 1.0 101 FFU/ml for theDENV-3 and -4 viruses,
respectively, while those of the multiplex CDC qRT-PCR were at
2.0  101 FFU/ml and 1.0  102 FFU/ml, respectively (see
Table S2a in the supplemental material). Therefore, the overall
analytical sensitivity of the pan-DENVRT-iiPCRwas comparable
to that of the multiplex CDC qRT-PCR in detecting viral RNA of
the field and laboratory strains.
In addition, the detection endpoints of both assays were com-
pared using the RNA extracted from 10-fold serial dilutions of the
TCF samples containing one of the prototype strains of DENV-1
to -4 (DENV-1/Hawaii A, DENV-2/New Guinea C, DENV-3/
H87, or DENV-4/H241). The pan-DENV RT-iiPCR and multi-
plex CDC qRT-PCR had the same detection endpoints for the
DENV-1, DENV-3 (4.9 FFU/ml), and DENV-4 (1.4 FFU/ml) vi-
ruses (see Table S2b in the supplemental material). For DENV-2/
New Guinea C, the detection endpoint of the pan-DENV RT-
iiPCR was at 9.7 101 FFU/ml, and that of the multiplex CDC
qRT-PCRwas at 9.7102 FFU/ml (Table S2b in the supplemen-
tal material). The results suggested that the detection limit of the
pan-DENV RT-iiPCR was comparable to that of the multiplex
CDCqRT-PCR for the prototypeDENV-1, -3, and -4 strainswhile
for the DENV-2 prototype strain it was about 10-fold lower than
that of the CDC qRT-PCR.
(ii) Analytical specificity. The specificity of the pan-DENV
RT-iiPCR was evaluated with viral nucleic acids extracted from
TCF samples containing hepatitis C virus, West Nile virus, Japa-
nese encephalitis virus, or influenza virus type A or B strains. The
newly established pan-DENV RT-iiPCR assay generated negative
signals with all of these viral pathogens (data not shown), imply-
ing a high analytical specificity.
(iii) Reproducibility. The reproducibility of the pan-DENV
RT-iiPCRwas evaluated using theRNAof the 2.7-FFU/mlDENV-
1/DenKor-02 sample. Target concentration in this sample was
approximately 10-fold above the detection limit of the pan-DENV
RT-iiPCR (the assay reached its detection limit for the virus at
2.7 101 FFU/ml). The test was done in six replicates per device
and repeated in three different POCKIT nucleic acid analyzers. All
reaction mixtures containing the target template showed positive
results (data not shown), indicating that the pan-DENV RT-
iiPCR could detect dengue viral RNA at concentrations close to its
detection limit with excellent reproducibility.
Evaluation of the pan-DENV RT-iiPCR using clinical sam-
ples.The clinical evaluation of the pan-DENVRT-iiPCRwas con-
ducted by testing 220 archived plasma samples collected from pa-
tients suspected of DENV infection over a period of 3 years (2011
to 2013) and 45 plasma specimens from subjects not suspected of
DENV infection in the study. First, these samples were tested by
the commercial NS1 antigen detection strip assay (dengueNS1 Ag
rapid test; StandardDiagnostics) at the time of sample submission
to the laboratory in Sri Lanka. Of the 265 samples, 142 (142/265)
were positive whereas 123 (123/265) samples were negative for
NS1 antigen. Subsequently, nucleic acids were prepared from
these archived samples and subjected to side-by-side testing with
the pan-DENVRT-iiPCR andCDCqRT-PCR.When the archived
samples were tested with the pan-DENV RT-iiPCR, 32 of the 142
NS1 antigen rapid test-positive samples tested negative for DENV
RNA (only 110/142 were positive). Furthermore, 25 of the 123
NS1 antigen-negative samples tested positive by the pan-DENV
RT-iiPCR (Table 1). Thus, 135/265 of the plasma samples were
positive by the pan-DENVRT-iiPCR. In summary, the agreement
between the RT-iiPCR and the NS1 antigen rapid test was about
78.5% (95% confidence interval [CI], 73.5 to 83.5%) with a kappa
value of 0.57 when the RNA extracted from plasma samples was
tested.
Although virus isolation (VI) is the gold standard for diagnosis
of DENV infection, only a few laboratories perform this assay
routinely (28). In most situations accurate diagnosis of dengue
virus infection can be best achieved by combining the detection of
virus (VI), viral nucleic acid (qRT-PCR), viral protein NS1 (NS1
antigen rapid test), and/or antibody response to the virus (ELISA)
(29, 30). Thus, a composite diagnosis of each sample based on two
out of the three methods (CDC qRT-PCR, NS1 antigen rapid test,
and pan-DENV RT-iiPCR) giving the same result was used as the
reference. A total of 135 out of the 265 samples were detected as
positive using the pan-DENV RT-iiPCR. The NS1 antigen rapid
TABLE 1 Diagnostic performance comparison between pan-DENV
RT-iiPCR and NS1 Ag rapid test methodsa
Pan-DENV RT-iiPCR result
No. of results with NS1
Ag rapid test that were:
TotalPositive Negative
Positive 110 25 135
Negative 32 98 130
Total 142 123 265
a Agreement (95% CI), 78.49% (73.51 to 83.47%).
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test and the CDC qRT-PCR detected 142 and 150 positive sam-
ples, respectively (Table 2). Of the 150 RT-qPCR positive samples,
145 were positive for DENV-1, and 5 samples were positive for
DENV-4 infection. Compared to the composite reference results,
the sensitivities of the pan-DENV RT-iiPCR, the NS1 antigen
rapid test, and the CDC qRT-PCR tests were 90.5% (95%CI, 85.5
to 95.4%), 84.3% (95% CI, 78.3 to 90.4%), and 98.6% (95% CI,
96.1 to 100%), respectively. The specificities of the pan-DENV
RT-iiPCR, the NS1 antigen rapid test, and the CDC qRT-PCR
tests were 98.3% (95% CI, 95.1 to 100%), 84.7% (95% CI, 78.1 to
91.4%), and 95.8% (95% CI, 91.6 to 99.9%), respectively (Table
2). Based on the analysis of the 265 clinical plasma specimens, the
pan-DENV RT-iiPCR, the NS1 antigen rapid test, and the CDC
qRT-PCR tests had an agreement of 93.9% (95% CI, 90.9 to
96.9%;   0.88), 84.5% (95% CI, 80.1 to 88.9%;   0.69), and
97.4% (95% CI, 95.2 to 99.5%;   0.95), respectively, with the
composite reference results for DENV detection in patient sam-
ples. In summary, compared to the composite reference results,
the pan-DENVRT-iiPCR test had 90.5% sensitivity (95%CI, 85.5
to 95.4%), 98.3% specificity (95% CI, 95.1 to 100%), and 93.9%
agreement (95% CI, 90.9 to 96.9%;   0.88).
DISCUSSION
DENV infections can result in a range of clinical manifestations
from asymptomatic infection to DF and DHF/DSS. The clinical
presentation of acute dengue virus infection is nonspecific, and 5
to 10% of patients progress to severe DHF/DSS, which can result
in death if not managed appropriately. Diagnosis of dengue virus
infection solely based on clinical symptoms is difficult since some
infections can resemble other diseases with similar clinical presen-
tations (such asmalaria, leptospirosis, typhoid, typhus, chikungu-
nya, and Zika). Sri Lanka is considered a hyperendemic region (a
category A country according to the World Health Organization)
for DENV infection. The disease is considered a major public
health concern locally. Since the early 2000s, large epidemics have
occurred at regular intervals in urban areas, involving cocircula-
tion of all four DENV serotypes (31). Despite the high dengue
fever burden occurring in Sri Lanka and other developing coun-
tries, access to good-quality diagnostic testing is lacking due to
limited laboratory infrastructure, technical expertise, and re-
search capacity. PON diagnostics could help shift health services
more to local levels, reduce costs and turnaround time, and
achieve disease diagnosis at early stages, improving health man-
agement quality in underreached communities. Thus, there is a
need for specific, inexpensive dengue virus diagnostic tests that
can be used for clinical management, surveillance, and outbreak
investigations to allow early intervention to treat patients and pre-
vent or control epidemics. Furthermore, a recombinant live atten-
uated tetravalent dengue vaccine based on the attenuated yellow
fever (YF) vaccine virus YF-17D was developed, and this vaccine
has now been introduced into the market in some countries
around the world (32). The new vaccine consists of four recombi-
nant viruses, expressing the premembrane (prM) and envelope
(E) proteins of DENV serotypes 1 to 4 (33, 34). Therefore, the
administration of the new recombinant live virus vaccine will
complicate the serological diagnosis of dengue virus infection us-
ing current IgM/IgG immunoassays whichmostly detect antibod-
ies to structural proteins (prM/M and E). Current serological as-
says use an IgM/IgG ratio of 0.5 as indicative of a primary DENV
infection. High levels of IgG in acute-phase samples define sec-
ondary infections (35). Thus, having a PON assay like the RT-
iiPCR described in the manuscript would be useful to diagnose
DENV infection in populations that are vaccinated against dengue
virus.
As described, a pan-DENV RT-iiPCR assay which utilized the
iiPCR technology was developed. The assay was carried out in the
R-tube within a field-deployable device, the POCKIT nucleic acid
analyzer (GeneReach USA, Lexington, USA) (21). In addition,
iiPCR assays prepared in lyophilized format could be shipped at
ambient temperatures and stored for at least 2 years at room tem-
perature, greatly reducing shipping and storage costs for diagnos-
tic laboratories. Thus, the simplicity and efficiency of the RT-
TABLE 2 Diagnostic sensitivity and specificity of pan-DENV RT-iiPCR, CDC qRT-PCR, and NS1 Ag rapid test for detection of dengue
virus infection
Assay and result
No. of results with the
composite set that were:a
Total
% sensitivity
(95% CI)
% specificity
(95% CI)
% agreement
(95% CI)Positive Negative
Pan-DENV RT-iiPCR 90.5 (85.5–95.4) 98.3 (95.1–100) 93.9 (90.9–96.9)
Positive 133 2 135
Negative 14 116 130
Total 147 118 265
NS1 Ag rapid test 84.3 (78.3–90.4) 84.7 (78.1–91.4) 84.5 (80.1–88.9)
Positive 124 18 142
Negative 23 100 123
Total 147 118 265
CDC qRT-PCR 98.6 (96.1–100) 95.8 (91.6–99.9) 97.4 (95.2–99.5)
Positive 145 5 150
Negative 2 113 115
Total 147 118 265
a A composite diagnosis for each sample based on two out of three methods giving the same result was used as the reference.
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iiPCR coupledwith the POCKITnucleic acid analyzer (RT-iiPCR/
POCKIT) to rapidly amplify nucleic acids under isothermal
conditions suggested that this assay could be a potential alterna-
tive for detection of DENV especially in remote field settings. This
system has been shown to offer sensitivity, specificity, and clinical
performance comparable to those of reference real-time PCR or
nested PCR methods for various microbial pathogens in various
clinical sample types (36–45). One of the major advantages of
RT-iiPCR is its simple protocol. Assembly of the reactionmixture
involves only three simple steps: (i) rehydration of the lyophilized
reagents, (ii) addition of sample nucleic acids, and (iii) transfer of
the reaction mixture into reaction tubes and placement on the
POCKIT nucleic acid analyzer. This simple automatic detection
module (POCKIT) made the method rather user-friendly. The
reaction could be completed in 1 h. In combination with the
easy, field-deployable manual and/or automatic nucleic acid
extraction methods available (PetNAD nucleic acid co-prep kit
and taco mini-nucleic acid automatic extraction system, re-
spectively; GeneReach), the iiPCR/POCKIT system is ready to
serve as a point-of-need pathogen detection tool to facilitate dis-
ease management, surveillance, and control.
In this study, the analytical sensitivity, specificity, and repeat-
ability of the pan-DENV RT-iiPCR/POCKIT system were evalu-
ated. The test was shown to be analytically specific and did not
cross-react with other important flavivirus pathogens such as Jap-
anese encephalitis virus, West Nile virus, and hepatitis C virus.
The emerging Zika virus is also a member of the genus Flavivirus
and is very closely related to Japanese encephalitis virus (2, 5).
Bioinformatic analysis of the genome sequences (n 13) of Zika
virus strains available in GenBank indicated that although signif-
icant homology was found in the 3=UTRof the Zika virus genome
(GenBank accession number KU820897.1 as a representative) for
the forward primer (91.3% identity) of the pan-DENV RT-iiPCR
assay, relatively low homology was found in the target sequences
for the reverse primer (68.2% identity) and probe (36.8% iden-
tity). Thus, the risks of the assay to cross-react with Zika virus
should be extremely low.
The relative sensitivities of the pan-DENV RT-iiPCR and the
multiplex qRT-PCR differed slightly depending on the DENV se-
rotype. With RNA prepared from laboratory or prototype DENV
strains, the pan-DENV RT-iiPCR generally rendered sensitivity
equal or comparable (	 1 log unit) to that of the multiplex qRT-
PCR assay (see Table S2 in the supplemental material). These mi-
nor differences in sensitivities with different DENV strains could
not be explained solely by the design of primers and probes. For
instance, although different relative sensitivities between RT-
iiPCR and qRT-PCR were observed with the two DENV-2 strains
(GenBank accession numbers KP406804 and AF038403) (23, 25,
46), no mismatches were found in the target regions of the primers
and probe of the pan-DENV RT-iiPCR in the two strains (see the
supplemental data). Similar observations were made with the
DENV-3 (GenBank accession number KP406805 andM93130) and
DENV-4 (GenBank accession number KP406806 and AY947539)
strains (23, 25, 46).Onepossible explanation is thatprimerandprobe
binding efficiencies could be affected by the stem-loop structures in
the 3=UTR of the RNA genome, which could be different due to the
significant sequence divergence, including mutations and deletions,
found locally in the3=UTRandremote regions in theDENVgenome
(46). Furthermore, the 3= end and 5= end of DENV viral genome are
known to interact with each other (47), and prominent sequence
heterogeneity was also found among the four serotypes in the 5= end
of DENV genome (46).
When both PCR assays were compared to the composite refer-
ence results, the pan-DENVRT-iiPCR demonstrated a promising
clinical performance, with 90.5% sensitivity and 98.3% specificity,
which were comparable to the 98.6% sensitivity and 95.8% spec-
ificity of the CDC qRT-PCR. Both methods had higher sensitivi-
ties and specificities than the NS1 antigen rapid test kit (84.3%
sensitivity and 84.7% specificity), which was consistent with the
observation that immunoassays had lower clinical performance
than PCR assays in general (28). However, compared to the RT-
iiPCR/POCKIT and the CDC qRT-PCR methods, the NS1 Ag
rapid test was simple and rapid.
When the clinical samples were tested with the three assays
(NS1 Ag rapid test, CDC qRT-PCR, and pan-DENV RT-iiPCR),
several disagreements were found between the test results that
could be due to multiple reasons. Of the three direct diagnostic
methods used in this study, two detected the viral RNA in plasma
(the CDC qRT-PCR and the pan-DENV RT-iiPCR), whereas the
NS1 Ag rapid test assay detected the viral antigen present in
plasma. It has been reported that the viral nucleic acids can be
reliably detected during viremia (5 days after the onset of illness)
(28; http://www.cdc.gov/dengue/clinicalLab/realTime.html). In
addition, qRT-PCRs could also detect viral RNA up to 10 days
after the onset of clinical symptoms in some clinical cases (48).
Similarly, NS1 antigen could be detected up to 9 days after the
onset of clinical symptoms in patientswith primary and secondary
dengue virus infections (28, 49). However, the plasma samples
used in this study were not sequential clinical samples from a
single patient but random clinical samples from individuals who
visited the clinic. Therefore, it was not clear whether these patients
had primary or secondary dengue virus infection or at what stage
of infection they were when the samples were collected (i.e., how
many days after the onset of clinical signs). A better understanding
of DENV replication and individual variation in host response, as
well as the collection and handling of specimens, is required to
better explain the reasons for the discrepancies between the two
assay systems (nucleic acid detection and NS1 antigen detection).
Moreover, the discrepancies between the CDC qRT-PCR and the
pan-DENV RT-iiPCR results are difficult to explain, but the sec-
ondary structures (such as the stem-loop structure in the 3=UTR)
in the target sequences and RT-PCR conditions used in these as-
says could give rise to discrepancies in results. The results of sev-
eral studies have suggested that the sensitivities of RT-PCR and
qRT-PCR depend on the region of the genome that is chosen to be
amplified and on the primers (and probes, in the case of qRT-PCR
assays) used to achieve this goal (48). It has been reported that
RT-PCR can be type specific in terms of DENV detection, and the
detection threshold is usually less than 100 PFU for all the sero-
types (48). Regrettably, the clinical samples included in this study
were mainly from patients infected with DENV-1 (n 145) and a
few infected with DENV-4 (n 5). Studies to improve the sensi-
tivity of the pan-DENV RT-iiPCR by changing the reaction con-
ditions to achieve sensitivity equivalent to or higher than that of
the CDCqRT-PCR are in progress.We plan to further validate the
new and improved pan-DENV RT-iiPCR with a significantly
larger number of clinical samples that are collected in a methodi-
cal manner (i.e., sequential clinical samples with detailed clinical
histories and significant samples to cover all four DENV serotypes
and multiple genotypes within a serotype) in the near future.
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The POCKIT Xpress portable PCR platform (consisting of a
POCKIT, a microcentrifuge, micropipettes, and consumables)
along with the lyophilized pan-DENV RT-iiPCR reagents (Gene-
Reach USA) offers much shorter single-reaction setup time and
setup-to-result time than those of the conventional RT-PCR. In
addition, its capacity to process eight reactionmixtures in one test
run makes the POCKIT system suitable in the near-patient set-
tings where the sample number is small and a sophisticated testing
procedure is not possible. Although the POCKIT system shows
good sensitivity for DENV detection, the samples would still need
to be referred to a centralized laboratory for serotype identifica-
tion in the case of epidemiologicalmonitoring. Although it cannot
provide the amount of information available from a serotype-
specific multiplex qRT-PCR, the POCKIT system can serve as an
alternative for the molecular diagnosis and routine screening of
DENV infections, especially in countries where dengue virus in-
fection is endemic. In summary, the pan-DENV RT-iiPCR cou-
pled with the POCKIT Xpress portable PCR platform is a good
candidate as a rapid, specific, and sensitive tool for use as a PON
test system in routine diagnosis of DENV infection.
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